BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

533 related articles for article (PubMed ID: 21160084)

  • 1. Aldosterone antagonists in heart failure.
    Guglin M; Kristof-Kuteyeva O; Novotorova I; Pratap P
    J Cardiovasc Pharmacol Ther; 2011 Jun; 16(2):150-9. PubMed ID: 21160084
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Eplerenone: a selective aldosterone receptor antagonist for hypertension and heart failure.
    Moore TD; Nawarskas JJ; Anderson JR
    Heart Dis; 2003; 5(5):354-63. PubMed ID: 14503934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eplerenone: a selective aldosterone receptor antagonist for patients with heart failure.
    Barnes BJ; Howard PA
    Ann Pharmacother; 2005 Jan; 39(1):68-76. PubMed ID: 15590870
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of aldosterone receptor antagonists in the management of heart failure: an update.
    Nagarajan V; Chamsi-Pasha M; Tang WH
    Cleve Clin J Med; 2012 Sep; 79(9):631-9. PubMed ID: 22949344
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The EMPHASIS-HF study].
    Boccanelli A; Agostoni P
    G Ital Cardiol (Rome); 2011 May; 12(5):315-8. PubMed ID: 21593949
    [No Abstract]   [Full Text] [Related]  

  • 6. Mineralocorticoid receptor antagonists for heart failure.
    Richards AM
    Expert Opin Pharmacother; 2011 Dec; 12(18):2801-15. PubMed ID: 22082128
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The risks and benefits of aldosterone antagonists.
    Sica DA
    Curr Heart Fail Rep; 2005 Aug; 2(2):65-71. PubMed ID: 16036053
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Aldosterone antagonists: characteristics, mechanisms of action, pharmacokinetics, indication, contraindication, clinical data, and side effects].
    Yamamoto T
    Nihon Rinsho; 2007 May; 65 Suppl 5():102-6. PubMed ID: 17571373
    [No Abstract]   [Full Text] [Related]  

  • 9. Aldosterone receptor antagonists in the medical management of chronic heart failure.
    Tang WH; Parameswaran AC; Maroo AP; Francis GS
    Mayo Clin Proc; 2005 Dec; 80(12):1623-30. PubMed ID: 16342656
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Review article: eplerenone: an underused medication?
    Abuannadi M; O'Keefe JH
    J Cardiovasc Pharmacol Ther; 2010 Dec; 15(4):318-25. PubMed ID: 20876342
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eplerenone--a novel selective aldosterone blocker.
    Zillich AJ; Carter BL
    Ann Pharmacother; 2002 Oct; 36(10):1567-76. PubMed ID: 12243608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mineralocorticoid receptor antagonists in heart failure with preserved ejection fraction (HFpEF).
    Capuano A; Scavone C; Vitale C; Sportiello L; Rossi F; Rosano GM; Coats AJ
    Int J Cardiol; 2015 Dec; 200():15-9. PubMed ID: 26404747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eplerenone: cardiovascular protection.
    Brown NJ
    Circulation; 2003 May; 107(19):2512-8. PubMed ID: 12756192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Aldosterone receptor blockade after acute myocardial infarction with heart failure].
    Bauersachs J; Ertl G
    Med Klin (Munich); 2006 Jun; 101(6):458-66. PubMed ID: 16767569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blocking aldosterone in heart failure.
    Shafiq MM; Miller AB
    Ther Adv Cardiovasc Dis; 2009 Oct; 3(5):379-85. PubMed ID: 19661156
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New treatment option for heart failure patients: eplerenone.
    Southworth MR; Cavallari LH
    J Cardiovasc Nurs; 2004; 19(6):390-5. PubMed ID: 15529060
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expanding role of mineralocorticoid receptor antagonists in the treatment of heart failure.
    Talatinian A; Chow SL; Heywood JT
    Pharmacotherapy; 2012 Sep; 32(9):827-37. PubMed ID: 22949142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hyperkalaemia in the age of aldosterone antagonism.
    Chapagain A; Ashman N
    QJM; 2012 Nov; 105(11):1049-57. PubMed ID: 22723454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety profile of mineralocorticoid receptor antagonists: Spironolactone and eplerenone.
    Lainscak M; Pelliccia F; Rosano G; Vitale C; Schiariti M; Greco C; Speziale G; Gaudio C
    Int J Cardiol; 2015 Dec; 200():25-9. PubMed ID: 26404748
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Eplerenone for the treatment of cardiovascular disorders.
    Watanabe M; Krum H
    Expert Rev Cardiovasc Ther; 2012 Jul; 10(7):831-8. PubMed ID: 22908915
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.